Editorial
'Run out and get me a four-year-old child' Many years ago in the film Duck Soup Groucho Marx as President of the mythical Freedonia observed that some item of government business was so simple that even a 4-year-old child could understand it (and then whispered quickly to an aide to run out and get a 4-year-old child, as he could not make head or tail of the plan). By analogy, many physicians with an interest in lupus fail to see the need to derive complex indices for determining how active systemic lupus erythematosus (SLE) may be in their patients. Surely a simple form of physician's overall assessment will suffice, i.e. the equivalent of a 4-year-old child! This argument is superficially difficult to counter, not least because of the absence of any 'gold standard' against which lupus activity may be formally compared. Even antibodies to double-stranded DNA may be absent in up to half the patients who meet the American College of Rheumatism's criteria for SLE. Furthermore, given a disease that can affect so many organs and systems, how could an index possibly hope to reflect truly the variety of potential involvement?
Despite the lack of enthusiasm in some quarters, during the last 30 years some 60 different indices purporting to reflect disease activity in SLE have been published (as reviewed elsewhere'). There has been little, if any, attempt to validate most of these indices. In addition, many have been fundamentally flawed by an attempt to equate, in too simplistic a manner, disease activity with the number of systems involved, while paying too little attention to the severity within any individual system.
The end result is a loss of common sense in the application of the index. Consider, for example, a patient with lymphadenopathy, lethargy, a minor skin rash, mild pleuritic pain and arthralgia who remains able to work. Such a patient could well be given a higher score than a patient who may have developed only disease in her kidneys, but may be seriously ill. Furthermore, few indices take any account of the rate of development of the symptoms or the time period for which they have been present. Finally, no index has really grasped the nettle of distinguishing what is actually damage due to previous inflammatory changes from what is truly current active disease. This final point may be particularly important since there is, for example, very little point in treating a lupus patient with major immunosuppressive drugs whose breathlessness is not due to active vasculitis but to fibrosed lungs or whose proteinuria is not due to active glomerulonephritis but is the consequence of glomerular sclerosis. There do, however, remain cogent reasons for attempting to assess disease activity in lupus in a more formal way. The very diversity of clinical features in SLE necessitates a uniform approach to the determination of disease activity in multicentre studies of therapy, autoantibody levels, analyses of differences in clinical features in various ethnic groups etc. Many aspects of the immune system are malfunctioning in SLE and, as indicated above, the absence of a gold standard implies a continuing search for an improved immunological parameter to distinguish patients whose disease is truly active in whatever system. There remains, therefore, a limited requirement for a global index in order to facilitate such multi-(or even single-) centre trials. In the past few years two global indices, SLEDAI (Systemic lupus erythematosus disease activity index)' z and SLAM (Systemic lupus activity measures)3, have been developed and validated after considerable thought and practice on both 'paper' and real patients. The indices can be applied from a similar database and in collaborative studies have shown a good overall con-cordance3, 5, 6. More recently a group of interested physicians under the direction of Dr Stefano Bombardieri have developed a European Index, which has also been shown to correlate well with these other two indices?.
There are now thus three good clinical indices that have been intervalidated, and it is the fervent hope of many that this era of the search for a global index for lupus is now over.
However, what would appear to be far more useful than a global index is one that distinguishes the type of involvement in any given patient and takes note of the time period during which the symptoms have evolved and/or disappeared. To meet these needs, the BILAG (British Islets Assessment Group) is now widely available and fully computerized 8. It is based on the principle of a physician's intention to treat, and reflects the actual practice of British rheumatologists from six different centres. Activity in lupus has been divided into eight organs or systems: general, mucocutaneous, nervous system, locomotor system, cardiovascular respiratory system, vasculitis, renal system and haematological. From major immunosuppressive therapy) to E (no involvement currently or previously). Although it can be converted into a global score and has been for the purposes of, successfully, comparing the index with SLAM, SLEDAI and some other indices', this was not the original intention of those who developed it and is not its primary function. It now offers the interested physician a relatively simple way of recording precisely the level of lupus activity in the major organs or systems, at each clinic appointment. The availability of a standard form to record the information needed to obtain a BILAG score is of value, not least to the rheumatologist who is away from the clinic but who can be secure in the knowledge that the junior staff are collecting the same data as he or she would have.
It is now surely time for us to move from the era of seeking yet more lupus activity indices to an era in which we accept that the talking has gone on for long enough, that several good indices are available, have been validated and seem by and large to be interchangeable. It is therefore time to move from a period of talking but little concerted action to one of action with less talking -in other words from the Groucho era to the Harpo era!
